Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI’s clinical services include expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US. Cancer Genetics Inc (CGIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on... Research Beam Model: Research Beam Product ID: 1915772 250 USD New
Cancer Genetics Inc (CGIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Cancer Genetics Inc (CGIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : July   2017
  • Pages : 42
  • Publisher : GlobalData
 
 
 
Summary

Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI’s clinical services include expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cancer Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Cancer Genetics Enters into Agreement with Lantern Pharma 12
Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 12
Cancer Genetics Enters into Agreement with BeiGene 13
Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 14
Cancer Genetics Partners with H3 Biomedicine 14
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 15
Mayo Clinic Forms Joint Venture With Cancer Genetics 16
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 17
Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 18
Aptiv Solutions Enters Into Joint Venture Agreement With Cancer Genetics 18
Equity Offering 19
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 19
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 21
Cancer Genetics Raises USD12 Million in Public Offering of Shares 22
Acquisition 23
Cancer Genetics Acquires Gentris for USD4.75 Million 23
Cancer Genetics Inc - Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 28
Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 30
Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability 32
Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates 34
May 10, 2016: Cancer Genetics Announces 39% Revenue Increase and Provides Recent Company Highlights 36
Mar 10, 2016: Cancer Genetics Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update 38
Corporate Communications 39
Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance 39
Other Significant Developments 40
Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 40
May 04, 2016: Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Cancer Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cancer Genetics Enters into Agreement with Lantern Pharma 12
Cancer Genetics Enters into Agreement with Biotech and Pharma Companies 12
Cancer Genetics Enters into Agreement with BeiGene 13
Cancer Genetics Enters into Co-Marketing Agreement with Bio Analytical Research 14
Cancer Genetics Partners with H3 Biomedicine 14
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 15
Mayo Clinic Forms Joint Venture With Cancer Genetics 16
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 17
Gentris Enters Into Co-Development With Shanghai Institutes of Preventive Medicine 18
Aptiv Solutions Enters Into Joint Venture Agreement With Cancer Genetics 18
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 19
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 21
Cancer Genetics Raises USD12 Million in Public Offering of Shares 22
Cancer Genetics Acquires Gentris for USD4.75 Million 23
Cancer Genetics Inc, Key Competitors 25
Cancer Genetics Inc, Key Employees 26
Cancer Genetics Inc, Other Locations 27
Cancer Genetics Inc, Subsidiaries 27List of Figures
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cancer Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 10
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter